Amicus Therapeutics Inc (MEX:FOLD)
MXN 208.8 0 (0%) Market Cap: 60.68 Bil Enterprise Value: 64.66 Bil PE Ratio: 0 PB Ratio: 16.63 GF Score: 78/100

Amicus Therapeutics Inc to Discuss the Clinical Pompe Disease Data and Preclinical Batten Disease Data Presented at the WORLDSymposium Transcript

Feb 07, 2019 / 12:00AM GMT
Sara Pellegrino
Amicus Therapeutics, Inc. - Senior Director of IR

Hi, good evening, everybody. Thank you for coming. Welcome to (inaudible) for tonight is John Crowley, Chairman and CEO, who will be opening up with a brief introduction. And then we will review the Pompe and Batten data filing. And we also have Dr. Hung (inaudible) today. (inaudible) we're going to ask that you hold your questions until the end of the session. All our speakers will be (inaudible). So with that, I'd like to now turn it over to John Crowley, Chairman and CEO.

John F. Crowley
Amicus Therapeutics, Inc. - Chairman & CEO

Great. Thanks, Sara. Good evening, everybody. Thanks for coming. I don't know if you've had the chance to get over yet [on reading that Page 2 and 3 of the release] of the packet (inaudible). I continue to be impressed with the number of people within organizations, entities and all, the resources (inaudible). (inaudible) for those of us who were there in the first year -- couple of years came up with really good stuff [with all the] people involved, the

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot